Q-omics provides the consensus-scored KLHL34 profile across patient tissues and cancer cell-line models. KLHL34 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KLHL34 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, KLHL34 RNA expression shows 14,642 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight UVM, COAD, and PCPG as cancer lineages where KLHL34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL34 survival associations across molecular data types. KLHL34 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL34 RNA expression–survival associations across cancer types. High KLHL34 expression shows unfavorable associations in CESC, but favorable associations in UVM, SCLC, BRCA, ESCA and CHOL. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for KLHL34 RNA expression.
This table summarizes KLHL34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KLHL34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL34 shows lower tumor expression in COAD, BLCA, KIRC, READ and STAD and higher tumor expression in LUAD. The COAD box plot shows higher KLHL34 RNA expression in normal versus tumor tissue (log2 FC = −1.117, t-test p < 0.001).
This table shows molecular features associated with KLHL34 in patient tissues and cancer cell lines. In patient samples, KLHL34 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL34 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
